A somewhat obscure federal program designed to reduce drug prices for health providers is getting scrutiny from lawmakers this year, with many questioning whether those savings are being used ...

Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described ...

The 340B drug pricing program is complicated. A clinic leader and a hospital said that’s making it easy for there to be misunderstandings about if the savings are being passed onto the patient.

Eli Lilly expand 340B reporting requirements to include all covered entities submitting claims-level data by Feb. 1, 2026, with some state exemptions.

NuvemRx, a leading tech-enabled pharmacy solutions company for community health providers, today announced it has acquired ...

The heavily scrutinized 340B Drug Pricing Program is back in the spotlight as the Trump administration targets drug costs in a recent Executive Order. The 340B Drug Pricing Program has received a lot ...

340B covered entities should carefully review the approved 340B rebate models and the 2026 Medicare Physician Fee Schedule (MPFS) Final Rule provisions on new CMS processes for identifying Medicare ...

By virtue of its exclusive contract to manage the 340B Drug Pricing Program since 2004, Apexus has become a government-sanctioned entity fraught with self-dealing interests in the 340B marketplace.

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...